Shares of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) have been given a consensus rating of “Hold” by the thirteen analysts that are currently covering the firm. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $15.56.
Several analysts have commented on the stock. BTIG Research restated a “buy” rating and issued a $18.00 price objective (up from $15.00) on shares of Ironwood Pharmaceuticals in a report on Friday, September 23rd. WallachBeth Capital raised their price objective on shares of Ironwood Pharmaceuticals from $15.00 to $17.00 and gave the stock a “hold” rating in a report on Tuesday, September 27th. Zacks Investment Research lowered shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 20th. Barclays PLC raised their price objective on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock an “equal weight” rating in a report on Friday, August 5th. Finally, Wedbush restated a “neutral” rating and issued a $10.00 price objective on shares of Ironwood Pharmaceuticals in a report on Thursday, August 4th.
In related news, Director Lawrence S. Olanoff sold 3,200 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $13.72, for a total transaction of $43,904.00. Following the completion of the sale, the director now owns 29,305 shares of the company’s stock, valued at $402,064.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.17% of the company’s stock.
A number of large investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd bought a new stake in Ironwood Pharmaceuticals during the second quarter worth approximately $144,000. Parametrica Management Ltd bought a new stake in Ironwood Pharmaceuticals during the second quarter worth approximately $150,000. Prudential Financial Inc. increased its stake in Ironwood Pharmaceuticals by 12.5% in the second quarter. Prudential Financial Inc. now owns 12,614 shares of the company’s stock worth $165,000 after buying an additional 1,400 shares during the period. BNP Paribas Arbitrage SA increased its stake in Ironwood Pharmaceuticals by 114.2% in the third quarter. BNP Paribas Arbitrage SA now owns 10,767 shares of the company’s stock worth $171,000 after buying an additional 5,741 shares during the period. Finally, Meeder Asset Management Inc. bought a new stake in Ironwood Pharmaceuticals during the second quarter worth approximately $180,000. 93.96% of the stock is owned by institutional investors and hedge funds.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 15.92 on Monday. The stock has a 50 day moving average price of $14.50 and a 200 day moving average price of $12.74. Ironwood Pharmaceuticals has a 12-month low of $7.35 and a 12-month high of $16.17. The company’s market capitalization is $2.31 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. Ironwood Pharmaceuticals had a negative return on equity of 94.75% and a negative net margin of 45.21%. The company earned $54.40 million during the quarter, compared to analysts’ expectations of $54.49 million. During the same quarter last year, the business earned ($0.34) earnings per share. The business’s quarterly revenue was up 96.4% on a year-over-year basis. On average, analysts expect that Ironwood Pharmaceuticals will post ($0.75) EPS for the current year.